Archives

  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Z-DEVD-FMK: Irreversible Caspase-3 Inhibitor for Apoptosi...

    2026-02-13

    Z-DEVD-FMK: Irreversible Caspase-3 Inhibitor for Apoptosis and Neuroprotection

    Executive Summary: Z-DEVD-FMK is a cell-permeable, irreversible tetrapeptide inhibitor that selectively targets caspase-3 and also inhibits caspase-6, -7, -8, -10, and calpain, thereby blocking key apoptosis and necrosis pathways (APExBIO product page) [1]. This compound covalently binds the active site cysteine in caspases, irreversibly inhibiting their proteolytic function [1]. Z-DEVD-FMK has demonstrated robust neuroprotection in traumatic brain injury models, reducing lesion size and neuronal death [1]. In cancer research, especially melanoma, it is essential for dissecting caspase-3-dependent apoptosis, as shown by its capacity to rescue cells from far-infrared radiation-induced cell death (Zhao et al., 2025) [2]. Its insolubility in water/ethanol but high solubility in DMSO allows flexible stock preparation for diverse workflows [1].

    Biological Rationale

    Apoptosis is a genetically regulated form of programmed cell death, essential for tissue homeostasis and development (Zhao et al., 2025). Caspase-3 is a critical executioner protease in the apoptosis cascade, activated by both extrinsic (death receptor) and intrinsic (mitochondrial) pathways. Dysregulation of caspase-3 activity is implicated in cancer, neurodegeneration, and ischemic injury (Z-DEVD-FMK: Next-Generation Caspase-3 Inhibitor...). Z-DEVD-FMK enables targeted inhibition of caspase-3, facilitating the study of apoptosis mechanisms and the development of therapeutic strategies for diseases where cell death pathways are perturbed. Its dual inhibition of calpain, a calcium-dependent cysteine protease involved in necrotic and neurodegenerative processes, extends its utility to models of traumatic brain injury and neuroprotection (Z-DEVD-FMK: Irreversible Caspase-3 Inhibitor for Apoptosis...).

    Mechanism of Action of Z-DEVD-FMK

    Z-DEVD-FMK is a tetrapeptide analog containing a fluoromethyl ketone (FMK) moiety, which forms a covalent bond with the active site cysteine of target proteases. This irreversible binding inactivates caspase-3 and related enzymes, preventing the cleavage of key cellular substrates required for apoptosis progression (APExBIO). The compound is cell-permeable, allowing effective intracellular delivery. In addition to caspase-3, Z-DEVD-FMK inhibits caspase-6, -7, -8, -10, and calpain. This broad activity profile enables the blockade of multiple cell death modalities, including apoptosis and caspase-independent necrotic death (Strategic Modulation of Caspase and Calpain Pathways...).

    Evidence & Benchmarks

    • Z-DEVD-FMK rescued B16F10 melanoma cells from far-infrared radiation-induced apoptosis, confirming its functional inhibition of caspase-3 in vitro (Zhao et al., 2025).
    • Application of Z-DEVD-FMK in mouse models of traumatic brain injury led to reduced neuronal cell death and smaller lesion size (APExBIO).
    • Stock solutions are stable for several months at -20°C in DMSO, maintaining inhibitory potency after repeated freeze-thaw cycles (APExBIO).
    • The compound’s dual inhibition of calpain and caspases provides neuroprotection in in vitro and in vivo models of neuronal injury (Z-DEVD-FMK: Irreversible Caspase-3 Inhibitor for Apoptosis...).
    • Z-DEVD-FMK is insoluble in water and ethanol but dissolves at ≥60 mg/mL in DMSO with warming and sonication (APExBIO).

    Applications, Limits & Misconceptions

    Z-DEVD-FMK is widely used in apoptosis assays, cell viability studies, and neuroprotection experiments. It is essential for dissecting the caspase signaling pathway in cancer, particularly in studies of TRAIL-induced apoptosis and melanoma cell death (Zhao et al., 2025). The compound is also instrumental in translational models of traumatic brain injury and neurodegeneration, where its dual inhibition profile offers a unique tool for mechanistic studies.

    Common Pitfalls or Misconceptions

    • Z-DEVD-FMK does not inhibit serine proteases or non-cysteine-dependent proteases; its activity is limited to caspases and calpain.
    • It cannot reverse apoptosis once downstream DNA fragmentation has occurred; use as a pre-treatment is essential.
    • The compound is ineffective in water-based buffers; stock solutions must be made in DMSO to ensure solubility and activity.
    • Not all models of cell death are caspase-dependent; necroptotic or ferroptotic death pathways are unaffected by Z-DEVD-FMK.
    • High concentrations (>100 μM) may produce off-target effects; titrate carefully for each application.

    Workflow Integration & Parameters

    Z-DEVD-FMK is supplied as a solid and should be stored at -20°C. For use, prepare stock solutions in DMSO at concentrations ≥60 mg/mL; sonication and gentle warming aid dissolution (APExBIO). Working concentrations typically range from 10–100 μM in cell-based assays. Avoid freeze-thaw cycles by aliquoting stock solutions. Controls should include DMSO-only and, when feasible, an inactive peptide analog. For apoptotic pathway delineation, combine Z-DEVD-FMK with other pathway-specific inhibitors or genetic knockdown approaches (Z-DEVD-FMK: Unraveling Caspase and Calpain Pathways in Cancer and Neurodegeneration).

    Conclusion & Outlook

    Z-DEVD-FMK (SKU A1920, APExBIO) is a benchmark tool in apoptosis and neuroprotection research, enabling precise dissection of caspase-dependent and calpain-mediated cell death. Its robust evidence base, dual target profile, and user-friendly storage/solubility make it indispensable for cancer, brain injury, and neurodegenerative disease models. Future studies may further define its selectivity and potential off-target interactions in complex in vivo systems. For product details and ordering, see the Z-DEVD-FMK product page.